MCID: THY029
MIFTS: 52

Thyroid Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Thyroid Carcinoma

MalaCards integrated aliases for Thyroid Carcinoma:

Name: Thyroid Carcinoma 58 53 5 16 71
Thyroid Cancer 75 53 5 41
Malignant Neoplasm of Thyroid 71
Thyroid Neoplasm 71

Characteristics:


Prevelance:

6-9/10000 (Europe) 1-5/10000 (United States, Worldwide, Italy) 1-9/100000 (Worldwide, United Kingdom, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Germany, Ireland, Latvia, Lithuania, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands) 58

Age Of Onset:

Adult 58

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

UMLS via Orphanet 72 C0549473
Orphanet 58 ORPHA100088
UMLS 71 C0007115 C0040136 C0549473

Summaries for Thyroid Carcinoma

MedlinePlus: 41 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. It makes hormones that help the body work normally. There are several types of cancer of the thyroid gland. You are at greater risk if you: Are between ages 25 and 65 Are a woman Are Asian Have a family member who has had thyroid disease Have had radiation treatments to your head or neck You should see a doctor if you have a lump or swelling in your neck. Doctors use a physical exam, thyroid tests, other blood and imaging tests, and a biopsy to diagnose thyroid cancer. Treatment depends on the type of cancer you have and how far the cancer has spread. Many patients receive a combination of treatments. They may include surgery, radioactive iodine, hormone treatment, radiation therapy, chemotherapy, or targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

MalaCards based summary: Thyroid Carcinoma, also known as thyroid cancer, is related to thyroid carcinoma, familial medullary and differentiated thyroid carcinoma, and has symptoms including tinnitus, snoring and sore throat. An important gene associated with Thyroid Carcinoma is RET (Ret Proto-Oncogene), and among its related pathways/superpathways is Regorafenib Pathway, Pharmacodynamics. The drugs Parathyroid hormone and Cathine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and salivary gland.

Wikipedia: 75 Thyroid cancer is cancer that develops from the tissues of the thyroid gland. It is a disease in which... more...

Related Diseases for Thyroid Carcinoma

Diseases related to Thyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1380)
# Related Disease Score Top Affiliating Genes
1 thyroid carcinoma, familial medullary 33.1 TG RET MALAT1 BRAF
2 differentiated thyroid carcinoma 32.9 RET BRAF
3 thyroid gland anaplastic carcinoma 32.7 TG RET PTCSC3 BRAF
4 thyroid gland follicular carcinoma 32.6 TG RET BRAF
5 multiple endocrine neoplasia 32.4 TG RET NEAT1
6 multicentric papillary thyroid carcinoma 32.3 TG RET
7 papillary carcinoma 32.1 TG RET BRAF
8 thyroid gland mucoepidermoid carcinoma 32.1 TG PTCSC3
9 thyroid cancer, nonmedullary, 1 32.0 PVT1 PTCSC3 NEAT1 MALAT1 HOTAIR H19
10 thyroid tumor 31.8 RET BRAF
11 hashimoto thyroiditis 31.8 TG RET BRAF
12 nodular goiter 31.6 TG RET BRAF
13 follicular adenoma 31.5 TG RET BRAF
14 papillary thyroid microcarcinoma 31.4 TG BRAF
15 struma ovarii 31.1 TG RET BRAF
16 thyroid lymphoma 30.9 TG RET
17 adenocarcinoma 30.8 RET MALAT1 H19 BRAF
18 malignant struma ovarii 30.8 TG RET
19 thyroid gland papillary carcinoma 30.6 NEAT1 GAS5 BRAF
20 pituitary adenoma 30.5 RET MALAT1 HOTAIR H19
21 benign struma ovarii 30.4 TG RET
22 substernal goiter 30.4 TG RET
23 nonencapsulated sclerosing carcinoma 30.4 TG RET
24 neurofibromatosis 30.3 RET CDKN2B-AS1 BRAF
25 glioma susceptibility 1 30.2 FALEC CDKN2B-AS1 CASC2
26 ovarian germ cell cancer 30.2 TG RET
27 squamous cell carcinoma 30.1 UCA1 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
28 thyroid dyshormonogenesis 2a 30.0 TG RET
29 tall cell variant papillary carcinoma 29.9 TG RET BRAF
30 laryngeal squamous cell carcinoma 29.8 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
31 leukemia, chronic myeloid 29.8 UCA1 HOTAIR H19 BRAF
32 wilms tumor 5 29.8 H19 BRAF
33 lung cancer susceptibility 3 29.8 MALAT1 HOTAIR H19 GAS5 CASC2 BRAF
34 gastric adenocarcinoma 29.8 NEAT1 HOTAIR H19 BRAF
35 neuroblastoma 29.7 RET MALAT1 HOTAIR H19 GAS5
36 oral squamous cell carcinoma 29.7 UCA1 NEAT1 MALAT1 HOTAIR H19
37 tongue squamous cell carcinoma 29.6 UCA1 MALAT1 AFAP1-AS1
38 b-cell lymphoma 29.6 PVT1 MALAT1 HOTAIR GAS5
39 leukemia 29.5 NEAT1 MLF1 HOTAIR GAS5 CDKN2B-AS1 BRAF
40 kidney cancer 29.5 PVT1 MALAT1 HOTAIR H19 GAS5
41 leukemia, acute myeloid 29.3 UCA1 MLF1 MALAT1 HOTAIR CDKN2B-AS1
42 melanoma 29.2 UCA1 PVT1 MALAT1 HOTAIR H19 GAS5
43 endometrial cancer 29.2 UCA1 NEAT1 HOTAIR H19 GAS5 CASC2
44 cholangiocarcinoma 29.2 UCA1 PANDAR NEAT1 MALAT1 H19 BRAF
45 retinitis pigmentosa 11 29.1 UCA1 PVT1 NEAT1 HOTAIR GAS5 CDKN2B-AS1
46 esophagus squamous cell carcinoma 29.1 PVT1 MALAT1 HOTAIR GAS5 AFAP1-AS1
47 esophageal cancer 28.8 UCA1 PVT1 MALAT1 HOTAIR H19 GAS5
48 pancreatic ductal adenocarcinoma 28.7 UCA1 PVT1 MALAT1 HOTAIR H19 AFAP1-AS1
49 myeloma, multiple 28.7 UCA1 PVT1 MALAT1 HOTAIR H19 GAS5
50 renal cell carcinoma, nonpapillary 28.5 UCA1 RET PVT1 PANDAR MALAT1 HOTAIR

Comorbidity relations with Thyroid Carcinoma via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism
Lymphomatous Thyroiditis Postsurgical Hypothyroidism

Graphical network of the top 20 diseases related to Thyroid Carcinoma:



Diseases related to Thyroid Carcinoma

Symptoms & Phenotypes for Thyroid Carcinoma

UMLS symptoms related to Thyroid Carcinoma:


tinnitus; snoring; sore throat; coughing; vertigo/dizziness; equilibration disorder

Drugs & Therapeutics for Thyroid Carcinoma

Drugs for Thyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 283)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
2
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
3
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
6
Codeine Approved, Illicit Phase 4 76-57-3, 6854-40-6 5284371 5362471
7
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
8
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Lenvatinib Approved, Investigational Phase 4 417716-92-8 9823820
12
Selenium Approved, Investigational, Vet_approved Phase 4 7783-07-5, 7782-49-2 533
13
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
14 Analgesics, Non-Narcotic Phase 4
15 Analgesics Phase 4
16 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
17 Antipyretics Phase 4
18 Respiratory System Agents Phase 4
19 Antitussive Agents Phase 4
20 Analgesics, Opioid Phase 4
21 Narcotics Phase 4
22 Citrate Phase 4
23 Anesthetics, Intravenous Phase 4
24 Anesthetics, General Phase 4
25 Pharmaceutical Solutions Phase 4
26 Anesthetics Phase 4
27 Anti-Arrhythmia Agents Phase 4
28 Sodium Channel Blockers Phase 4
29 Anesthetics, Local Phase 4
30 Diuretics, Potassium Sparing Phase 4
31 Selenium Supplement Phase 4
32 Technetium Tc 99m Sestamibi Phase 4
33
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
34
Racepinephrine Approved, Vet_approved Phase 3 51-43-4, 329-65-7 838 5816
35
Dabrafenib Approved, Investigational Phase 3 1195765-45-7 44462760
36
Iodine Approved, Investigational Phase 3 7553-56-2 807
37
Pralsetinib Approved, Investigational Phase 3 2097132-94-8 129073603
38
Metformin Approved Phase 3 1115-70-4, 657-24-9 4091
39
Rivoceranib Investigational Phase 3 811803-05-1 11315474
40
Cadexomer iodine Experimental Phase 3 94820-09-4
41 3-Iodobenzylguanidine Phase 3
42 Neurotransmitter Agents Phase 3
43 Fibrin Tissue Adhesive Phase 3
44 Hemostatics Phase 3
45 Coagulants Phase 3
46 Vasoconstrictor Agents Phase 3
47 Epinephryl borate Phase 3
48 Bronchodilator Agents Phase 3
49 Adrenergic beta-Agonists Phase 3
50 Adrenergic alpha-Agonists Phase 3

Interventional clinical trials:

(show top 50) (show all 627)
# Name Status NCT ID Phase Drugs
1 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
2 Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial Unknown status NCT00385983 Phase 4
3 Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer? Completed NCT00604318 Phase 4 rhTSH
4 Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Completed NCT03969108 Phase 4 Indocyanine Green
5 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Completed NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
6 Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Completed NCT01308320 Phase 4 fentanyl citrate;saline
7 Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused Recruiting NCT05247476 Phase 4 L-T4;L-T4+T3 (thyroid tablet)
8 Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study) Recruiting NCT04574947 Phase 4 Intravenous lidocaine;Intravenous placebo
9 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
10 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Active, not recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
11 Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer Active, not recruiting NCT03573960 Phase 4 Lenvatinib
12 Distribution of Selenium in Patients With Differentiated Thyroid Carcinoma and Effect of Selenium Supplement on Prognosis of Patients With Differentiated Thyroid Carcinoma. Not yet recruiting NCT04683575 Phase 4 Selenium Yeast;Placebo
13 Efficacy Evaluation of Strontium-89 Chloride for Differentiated Thyroid Cancer With Bone Metastases Not yet recruiting NCT05466812 Phase 4 Sr-89
14 Evaluation of 99mTc Sestamibi Scans In Patients Who Have Differentiated Thyroid Cancer, Elevated Serum Thyroglobulin Levels, and Negative Diagnostic Imaging Studies Terminated NCT03065218 Phase 4 99mTc sestamibi
15 Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients Terminated NCT02946918 Phase 4 Levothyroxine
16 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
17 Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study Unknown status NCT01149161 Phase 2, Phase 3
18 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
19 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032) Unknown status NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
20 Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients Unknown status NCT02418247 Phase 2, Phase 3 I131;I123
21 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
22 Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
23 Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study Completed NCT01137097 Phase 2, Phase 3
24 Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections Completed NCT01126060 Phase 3 Usage of Fibrin sealant
25 Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) Completed NCT01083550 Phase 2, Phase 3
26 The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer Completed NCT00794053 Phase 3
27 An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer Completed NCT00704730 Phase 3 XL184;Placebo
28 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China Completed NCT02966093 Phase 3 Lenvatinib;Placebo
29 A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
30 Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
31 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer Completed NCT01321554 Phase 3 Lenvatinib;Placebo
32 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial Completed NCT00795782 Phase 3
33 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study Completed NCT01616316 Phase 2, Phase 3
34 Phase 3 Study of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy Completed NCT02112370 Phase 3 Ropivacaine with epinephrine injection
35 Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy Recruiting NCT04290663 Phase 3 Systematic RAI-treatment
36 A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Recruiting NCT04211337 Phase 3 Selpercatinib;Cabozantinib;Vandetanib
37 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Recruiting NCT03570021 Phase 3
38 A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC) Recruiting NCT04940052 Phase 3 Dabrafenib;Trametinib;Trametinib placebo;Dabrafenib placebo
39 An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal Recruiting NCT04971473 Phase 3
40 A Randomized, Open-label, Multi-center, Controlled Phase Ⅲ Study to Evaluate the Safety and Efficacy of Recombinant Human Thryoid Stimulating Hormone(rhTSH) for Adjuvant Radioiodine Ablation Therapy in Postoperative Patients With Differentiated Thyroid Cancer Recruiting NCT04964284 Phase 3
41 A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib Active, not recruiting NCT01298323 Phase 3 Vandetanib
42 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
43 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Active, not recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
44 A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer Active, not recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
45 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy Active, not recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
46 Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO] Active, not recruiting NCT00415233 Phase 3
47 A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy. Active, not recruiting NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
48 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Active, not recruiting NCT01398085 Phase 2, Phase 3
49 A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer. Not yet recruiting NCT04760288 Phase 3 Pralsetinib;Cabozantinib;Vandetanib
50 Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer Not yet recruiting NCT05468554 Phase 3 metformin

Search NIH Clinical Center for Thyroid Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2b
lenvatinib
levothyroxine
Levothyroxine Sodium
liothyronine
liothyronine sodium
sorafenib
Thyroglobulin
THYROID (BEEF)
thyroid (USP)
THYROID PWDR
thyrotropin alfa
Vandetanib

Genetic Tests for Thyroid Carcinoma

Anatomical Context for Thyroid Carcinoma

Organs/tissues related to Thyroid Carcinoma:

MalaCards : Thyroid, Lymph Node, Salivary Gland, Breast, Lung, Bone, Endothelial

Publications for Thyroid Carcinoma

Articles related to Thyroid Carcinoma:

(show top 50) (show all 44049)
# Title Authors PMID Year
1
High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. 62 5
23416954 2013
2
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. 62 5
16778204 2006
3
Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. 62 5
11389085 2001
4
Development and validation of a nomogram to predict cancer-specific survival in elderly patients with papillary thyroid carcinoma: a population-based study. 62 41
36076163 2022
5
Development and validation of a nomogram model for cancer-specific survival of patients with poorly differentiated thyroid carcinoma: A SEER database analysis. 62 41
36176465 2022
6
Efficacy and safety of ultrasound-guided radiofrequency ablation for papillary thyroid microcarcinoma: a systematic review and meta-analysis. 41
36195326 2022
7
INSL3 has tumor-promoting activity in thyroid cancer. 53 62
19950223 2010
8
Targeted therapy for thyroid cancer: An updated review of investigational agents. 53 62
20496261 2010
9
RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. 53 62
19898969 2010
10
Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels. 53 62
20075119 2010
11
The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. 53 62
20200941 2010
12
Cytokines, thyroid diseases and thyroid cancer. 53 62
20381375 2010
13
Diagnostic utility of galectin-3 in thyroid cancer. 53 62
20363921 2010
14
Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells. 53 62
20138958 2010
15
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. 53 62
19897009 2010
16
Relaxin enhances S100A4 and promotes growth of human thyroid carcinoma cell xenografts. 53 62
20332215 2010
17
Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness. 53 62
20392995 2010
18
Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases? 53 62
20464711 2010
19
Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer. 53 62
19636213 2010
20
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. 53 62
20127563 2010
21
Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. 53 62
19913280 2010
22
Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. 53 62
20332457 2010
23
Standard and emerging therapies for metastatic differentiated thyroid cancer. 53 62
20142332 2010
24
Selectively targeting mutant BRAF in thyroid cancer. 53 62
20056810 2010
25
Is there any venous gradient in serum thyroglobulin levels in patients with differentiated thyroid cancer? 53 62
20353278 2010
26
Recent advances in the research and development of B-Raf inhibitors. 53 62
20345352 2010
27
The level of TSH appeared favourable in maintaining bone mineral density in postmenopausal women. 53 62
20151763 2010
28
Small (<10 mm) thyroid nodules; how aggressively should they be managed? 53 62
20164665 2010
29
Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? 53 62
20017617 2010
30
Targeting the RET pathway in thyroid cancer. 53 62
19934298 2009
31
Detection of circulating thyroid cancer cells in patients with thyroid microcarcinomas. 53 62
19958935 2009
32
Clinical inquiries. What's the best way to monitor low-risk patients with a history of differentiated thyroid cancer? 53 62
19961815 2009
33
F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. 53 62
19851169 2009
34
[Usefulness of the determination of thyroglobulin in lymph node aspirates of patients with papillary thyroid carcinoma and positive antithyroglobulin antibodies]. 53 62
20096208 2009
35
Significance of marginally elevated calcitonin levels in micromedullary thyroid cancer. 53 62
19636626 2009
36
Evaluation of 18fluoro-2-deoxyglucose positron emission tomography in iodine scan negative, differentiated thyroid cancer recurrence. 53 62
19607742 2009
37
Ablative free thyroxine to thyroglobulin ratio as a predictor of differentiated thyroid cancer recurrence. 53 62
19769825 2009
38
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. 53 62
19878585 2009
39
Serum thyroglobulin measurement in the follow-up of patients treated for differentiated thyroid cancer. 53 62
19910901 2009
40
Kinase expression and chromosomal rearrangements in papillary thyroid cancer tissues: investigations at the molecular and microscopic levels. 53 62
20083851 2009
41
Radioiodine ablation: when and how. 53 62
19910900 2009
42
Molecularly targeted therapies for thyroid cancers. 53 62
19546052 2009
43
A microfluidic biosensor based on competitive protein adsorption for thyroglobulin detection. 53 62
19577460 2009
44
Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence. 53 62
19551443 2009
45
Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. 53 62
19678746 2009
46
BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. 53 62
19574281 2009
47
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid. 53 62
19524134 2009
48
Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. 53 62
19530676 2009
49
Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. 53 62
19652218 2009
50
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. 53 62
19480010 2009

Variations for Thyroid Carcinoma

ClinVar genetic disease variations for Thyroid Carcinoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RET NM_020975.6(RET):c.1900T>C (p.Cys634Arg) SNV Pathogenic
13917 rs75076352 GRCh37: 10:43609948-43609948
GRCh38: 10:43114500-43114500
2 ATM, C11orf65 NM_000051.4(ATM):c.7654C>A (p.His2552Asn) SNV Uncertain Significance
185440 rs786202174 GRCh37: 11:108202630-108202630
GRCh38: 11:108331903-108331903
3 BARD1 NM_000465.4(BARD1):c.632T>C (p.Leu211Ser) SNV Uncertain Significance
186956 rs762171436 GRCh37: 2:215645966-215645966
GRCh38: 2:214781242-214781242

Copy number variations for Thyroid Carcinoma from CNVD:

6 (show all 22)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 48476 11 1 43400000 Gain Thyroid cancer
2 75266 13 18400000 72100000 Loss Thyroid cancer
3 80538 13 93800000 114142980 Loss Thyroid cancer
4 85051 14 37800000 43500000 Copy number FOXA1 Thyroid cancer
5 96631 15 90931472 91045475 Amplificationlication IQGAP1 Thyroid cancer
6 111285 17 35400000 68400000 Gain Thyroid cancer
7 120295 18 23300000 71300000 Loss Thyroid cancer
8 150420 20 1 27100000 Amplification Thyroid cancer
9 151957 20 27100000 62435964 Amplification Thyroid cancer
10 153452 20 37100000 62435964 Gain Thyroid cancer
11 171643 3 170900000 182700000 Gain PIK3CA Thyroid cancer
12 171644 3 170900000 182700000 Gain PIK3CA Thyroid cancer
13 191662 5 1 45800000 Amplification Thyroid cancer
14 191664 5 1 45800000 Gain Thyroid cancer
15 200481 5 55800000 180857866 Gain Thyroid cancer
16 201091 5 65300000 159900000 Amplification Thyroid cancer
17 217036 7 1 158821424 Amplification Thyroid cancer
18 230743 8 1 19100000 Loss Thyroid cancer
19 236403 8 16100000 117700000 Amplification Thyroid cancer
20 236404 8 16100000 146274826 Gain Thyroid cancer
21 261707 X 24900000 59500000 Loss Thyroid cancer
22 303365 21 26028751 26066642 Deletion GABPA Thyroid cancer

Expression for Thyroid Carcinoma

Search GEO for disease gene expression data for Thyroid Carcinoma.

Pathways for Thyroid Carcinoma

Pathways related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.53 RET BRAF

GO Terms for Thyroid Carcinoma

Biological processes related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of miRNA-mediated gene silencing GO:0060965 9.13 NEAT1 PVT1
2 myeloid progenitor cell differentiation GO:0002318 8.92 MLF1 BRAF

Molecular functions related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 miRNA binding GO:0035198 8.92 PVT1 NEAT1 GAS5

Sources for Thyroid Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....